ClinicalTrials.gg
CompletedNCT07938138Updated Nov 16, 2026

Safety and Tolerability of F012 in Patients With Hyperuricemia and Gout

A Phase 1 interventional study of PEGylated uricase and F012 placebo in Hyperuricemia With or Without Gout and Gout, sponsored by The Affiliated Hospital of Qingdao University. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by The Affiliated Hospital of Qingdao University · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Jun 2024, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.

Enrollment
35th of 44
40 · median 93
Started
2024
with 4 others
Phase 1
16 of 49
4 open now
Registered
49th of 49
by date
Lead sponsor
3 of 49
The Affiliated Hospital of Qingdao University

Among the 49 studies in Gout with a site in China, this one is the 35th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2024, is one of 16 in phase 1, and was the 49th registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Gout with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled single dose escalation (SAD) study conducted in patients with hyperuricemia with or without gout. The plan is to conduct ramp ups in 5 dose groups of 1mg, 2mg, 4mg, 6mg, and 8mg (adjustable during the study), with 8 subjects in each dose group and a total of 40 subjects. The sentinel method will be used for each dose group, with 2 subjects in the first group (1A+1P) followed by 6 subjects in the second group (5A+1P), to observe safety and tolerability.

03

Conditions studied

  • Hyperuricemia With or Without Gout
  • Gout

Browse trials for

Keywords

  • PEGylated uricase
  • Phase I clinical trial
  • pharmacokinetics
  • immunogenicity
  • gout
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hyperuricemia patients: Stop uric acid lowering treatment for more than 7 days, and take two non same day treatments within 7 days.Fasting blood uric acid level ≥ 480 μ mol/L;
  2. Patients with or without occasional gout: Complies with the 2015 American College of Rheumatology ACR/European Union Against Rheumatism (EULAR) jointly launch diagnosis of gout standardized and screened with less than 2 gout attacks in the previous year;
  3. The weight of male subjects is ≥ 50.0kg, and the weight of female subjects is ≥ 45.0kg. Weight refers toBMI is between 18\~30kg/m2, including the critical value
  4. The subjects have a good daily routine and are able to maintain good communication and compliance with the researchersAdhere to various requirements of clinical trials;
  5. Voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or abnormal G6PD with clinical significance, history of catalase deficiency, history of diseases, and history of atopic allergic diseases;
  2. Those with a history of tuberculosis within 6 months before screening;
  3. Patients with secondary hyperuricemia;
  4. Malignant tumor patients;
  5. Organ transplant patients;
  6. Individuals with drug allergies;
  7. History of acute gout attacks within 2 weeks prior to the screening period or being in the acute gout attack phase at the time of screening;
  8. Patients with unstable angina pectoris, serious arrhythmia requiring drug intervention, congestive heart failure [ rating ≥ Grade II], uncontrolled hypertension (more than 150/95 mmHg), poor blood glucose control in diabetes patients (i.e. glycosylated ≥ 7%), acute stroke, severe or chronic hemorrhagic digestive system disease, pleural effusion, abdominal effusion, etc;
  9. Individuals with creatinine levels greater than 1.5 times the ; Individuals with serum transaminase levels exceeding 1.5 times the upper limit of normal range;
  10. Individuals who have previously received uricase therapy;
  11. Individuals with clear blood system disorders or abnormal coagulation function;
  12. Individuals with herpes zoster infection, uncorrected dehydration, acidosis, or currently using nephrotoxic drugs;
  13. Virological tests show positive results for antibodies, antibodies, and Treponema pallidum antibodies; : HBsAg and/or HBcAb positive individuals with HBV-DNA above the upper limit of normal values;
  14. Individuals with severe mental and psychological disorders, cognitive impairments, and a history of mental illness;
  15. Individuals with a tendency to bleed, such as those who experience bleeding or subcutaneous bleeding due to mild collisions during normal times;
  16. People who have difficulty with venipuncture, cannot tolerate venipuncture, and have a history of needle and blood dizziness;
  17. Those who have undergone surgical procedures within 3 months prior to the first administration, or plan to undergo surgical procedures during the study period;
  18. Individuals who have received any other clinical trial drug/device treatment within 3 months prior to the first administration;
  19. Those who consume more than 1L of strong tea, coffee, and/or caffeinated beverages per day within the first 3 months prior to the first administration; Eating high purine foods (such as animal organs, seafood, etc.) within 48 hours before administration;
  20. Individuals who donate blood or experience significant blood loss (≥ 400mL, excluding normal menstrual blood loss in females), receive blood transfusions, or use blood products within 3 months prior to the first administration of medication;
  21. Smoking ≥ 5 cigarettes per day within 3 months before the first administration, or unwilling to ban any tobacco products during the trial period;
  22. Positive alcohol breath test results, or those who have been drinking alcohol for more than 14 units per week within the past 3 months before the first administration (1 unit of alcohol equals approximately 285mL of beer, 25mL of strong liquor, or 100mL of wine);
  23. Individuals with a history of drug abuse (including repeated and excessive use of various types of narcotics and psychotropic drugs for non-medical purposes) or positive drug abuse screening results within one year prior to the first administration;
  24. Individuals who have received inactivated vaccines within one month prior to the first dose, received live/attenuated vaccines within three months prior to the first dose, or plan to receive any vaccines during the trial period;
  25. Female subjects who engage in unprotected sexual activity during pregnancy, lactation, or 2 weeks prior to administration, as well as those who have a pregnancy plan or a plan to donate sperm or eggs within 6 months after the end of the trial and are unwilling to use a medically recognized method (such as intrauterine devices or condoms) or abstain during the trial period;
  26. Those who may not be able to complete this study due to other reasons or who the researcher deems should not be included.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Placebo comparator
    Placebo group

    Single intravenous injection of placebo

    Drug: F012 placebo

  • Experimental
    F012 experimental group

    Single intravenous injection of F012

    Drug: PEGylated uricase

Interventions

  • DrugPEGylated uricase

    Dilute F012 into 0.9% sodium chloride injection solution. Inject 1mg, 2mg, and 4mg dose groups intravenously with a syringe pump, and 6mg and 8mg dose groups intravenously for at least 2 hours.

  • DrugF012 placebo

    Dilute placebo into 0.9% sodium chloride injection solution. Inject 1mg, 2mg, and 4mg dose groups intravenously with a syringe pump, and 6mg and 8mg dose groups intravenously for at least 2 hours.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Event and Serious Adverse Events

    Time frame: From dosing through Day 71

  2. Plasma Concentration of PEGylated uricase

    Time frame: Pre-dosing, immediately after the end of infusion, and 3, 4 , 8 , 12, 24 , 48 , 72 , 168 , 504 , 672 , 840 hours after dosing

Secondary outcomes

  1. Maximum Serum Concentration (Cmax)

    Time frame: From start infusion through 840h(D36) after dosing

  2. Area Under the Serum Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUC0-t)

    Time frame: From start infusion through 840h(D36) after dosing

  3. Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC0-∞)

    Time frame: From start infusion through 840h(D36) after dosing

  4. Time to Maximum Observed Serum Concentration (Tmax)

    Time frame: From start infusion through 840h(D36) after dosing

  5. Terminal Half-Life (t1/2)

    Time frame: From start infusion through 840h(D36) after dosing

  6. Serum Uric Acid Concentration

    Time frame: Pre-dosing, immediately after the end of infusion, and 3, 4 , 8 , 12, 24 , 72, 168 , 504,672,840 hours after dosing

  7. Number of Participants With Anti-Drug Antibodies

    Time frame: Pre-dosing and 168, 336, 504 , 840, 1680 hours after dosing

  8. Change From Baseline in QT Interval Corrected for Heart Rate (QTcF)

    Time frame: Pre-dosing and 2, 3 , 4, 8, 24 , 48 hours after dosing

07

Study locations

1 site
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jun 2025, 12 months.

Of 40 phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 12 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 16, 2026
StartActual
Jun 11, 2024
Primary completionActual
Jun 30, 2025
CompletionActual
Nov 30, 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938138
Responsible party
Cao Yu (Principal Investigator, The Affiliated Hospital of Qingdao University) — Principal investigator
First posted
Nov 16, 2026
Start date
Jun 11, 2024
Primary completion
Jun 30, 2025
Completion
Nov 30, 2025
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion